Alhalabi, Omar

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., et al. (2020) · Nature Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 318

Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study.

Lisberg, A., Drakaki, A., Meric-Bernstam, F., Alhalabi, O., Kojima, T., Kato, M., Spira, A. I., Salkeni, M. A., Heist, R., Gao, X., et al. (2024) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsLung Cancer Treatments and Mutations

Cited by 15